Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2022
2023
2024
2025
Fennec Pharmaceuticals Inc. (FENC)
Price$11.30Cached quote
Net income
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.6M | $47.5M | $23.8M | $1.8M | — | $170,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross profit | $40.9M | $44.4M | $20.0M | $1.4M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross margin | 91.57% | 93.30% | 84.07% | 81.91% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $250,000 | $307,000 | $56,000 | $3.5M | $5.0M | $5.1M | $5.6M | $5.0M | $1.9M | $472,000 | $256,000 | $357,000 | $597,000 | $2.1M | $1.5M | $708,000 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | $50.9M | $45.0M | $34.0M | $24.0M | $17.2M | $18.1M | $13.0M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | −$6.3M | $2.6M | −$12.8M | −$22.6M | −$17.2M | −$17.9M | −$13.0M | −$10.4M | −$7.0M | −$2.9M | −$1.9M | −$2.9M | −$1.9M | −$3.6M | −$3.4M | −$4.6M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −14.07% | 5.40% | −53.70% | −1,276.94% | — | −10,520.59% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$7.5M | $4.8M | −$12.4M | −$22.6M | — | — | — | — | — | — | — | — | −$1.9M | −$3.6M | −$3.4M | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA margin | −16.69% | 10.09% | −51.99% | −1,276.82% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$9.7M | −$436,000 | −$16.0M | −$23.7M | −$17.3M | −$18.1M | −$12.8M | −$9.9M | −$7.0M | −$2.8M | −$659,000 | −$2.2M | $1.8M | −$5.2M | $4.7M | −$7.8M | −$3.0M | −$13.6M | −$13.4M | −$16.4M | −$13.9M | −$6.9M | −$17.8M | −$3.7M | −$2.5M | −$1.6M | −$958,000 | −$398,000 | −$37,000 |
| Net profit margin | −21.82% | −0.92% | −67.47% | −1,340.53% | — | −10,652.35% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.34 | -$0.02 | -$0.60 | -$0.90 | -$0.67 | -$0.76 | -$0.64 | -$0.52 | -$0.47 | -$0.22 | -$0.06 | -$0.22 | $0.19 | -$0.63 | $0.60 | -$1.47 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.34 | -$0.02 | -$0.60 | -$0.90 | -$0.67 | -$0.76 | -$0.64 | -$0.52 | -$0.47 | -$0.22 | -$0.06 | -$0.22 | $0.17 | -$0.63 | $0.57 | -$1.47 | — | — | — | — | — | — | — | — | — | — | — | — | — |
Owners
Reported shareholders
9.10%of listed shares
Rosalind Advisors, Inc.3.19M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Rosalind Advisors, Inc. | 9.10%3.19M shares |
Southpoint Capital Advisors LP / Southpoint GP, LLC / Clark John Smith II / Southpoint GP, LP / Southpoint Capital Advisors LLC | ≈7.83%2.74M shares |
AIGH Capital Management LLC | 7.10%2.49M shares |
Solas Capital Management, LLC | 5.39%1.89M shares |
BlackRock, Inc. | 4.93%1.73M shares |
AWM Investment Company, Inc. | 3.31%1.16M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.40%839.31K shares |
Prospect Capital Advisors, LLC | 1.42%497.8K shares |
STATE STREET CORP | 1.22%426K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.15%402.57K shares |
Andrade Robert | ≈0.83%289.27K shares |
JANE STREET GROUP, LLC | 0.67%233.88K shares |
Potomac Capital Management, Inc. | 0.64%224.4K shares |
MORGAN STANLEY | 0.63%221.92K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.57%200K shares |
NORTHERN TRUST CORP | 0.48%167.92K shares |
MARSHALL WACE, LLP | 0.40%138.76K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.38%134.2K shares |
Nuveen, LLC | 0.38%131.48K shares |
Raykov Rosty | ≈0.37%130.08K shares |
Percentages use 35.03M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 1, 2026Form 4 · 10b5-1 | Raykov RostyDirector | SellCommon shares | 9.7K | $9.62 | $93.8K | 130.1K |
| May 11, 2026Form 4 · 10b5-1 | RALLIS CHRIS ADirector | SellCommon Shares | 8.3K | $7.04 | $58.8K | 63.1K |
| May 1, 2026Form 4 · 10b5-1 | Raykov RostyDirector | SellCommon shares | 10.8K | $6.47 | $69.8K | 121.5K |
| Apr 1, 2026Form 4 · 10b5-1 | Raykov RostyDirector | SellCommon shares | 10.9K | $6.31 | $69.1K | 113.9K |
| Mar 2, 2026Form 4 · 10b5-1 | Raykov RostyDirector | SellCommon shares | 10.1K | $8.36 | $84.3K | 104.0K |